Nirsevimab, a long-acting monoclonal antibody, was introduced last season (2023–2024) in some countries with the aim of ...

Nirsevimab implementation in Catalonia, Spain, reduced emergency department visits and hospital admissions for bronchiolitis ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

A single injection of nirsevimab, a long-acting monoclonal antibody developed to prevent respiratory syncytial virus (RSV) ...

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein ...

Further, the study showed that nirsevimab’s effect was less pronounced in older children (between six and 23 months), ...

Maternal vaccination and, to a lesser extent, nirsevimab appear to significantly reduce RSV-related hospitalizations in infants.

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...